SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community rallies to boost volume and build organic momentum while awaiting platform-wide ticker and charting support. Investors are actively debating the project's long-term sustainability and transparency, with many sharing bullish sentiment about its potential to disrupt the meme coin space.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as investors highlight its unique Layer 0 architecture and high-profile partnerships with U.S. government and defense agencies, including the Department of Defense and Air Force. Community discussions are centered on the project's pivot toward becoming core infrastructure for AI and real-world data validation, with significant buzz surrounding a recent acquisition-led growth strategy and the potential for mass enterprise adoption.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing significant volatility as investors weigh strong quarterly growth and major contract wins against mounting concerns regarding AI-driven disruption to the broader software sector. While the community remains deeply divided between those viewing the pullback as a structural repricing and those treating the current price as a long-term entry point, the stock is struggling to maintain support amidst intense selling pressure and a sector-wide rotation away from high-multiple SaaS names.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is experiencing significant volatility and heavy trading volume as investors react to a strategic pivot that includes a 40% workforce reduction and an intensified focus on its core ovarian cancer drug trial. Community sentiment is deeply polarized, with active discussions debating whether the stock is a deep-value buyout target trading below its cash-on-hand valuation or a speculative gamble facing long-term dilution risks.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is experiencing high volatility as the stock reacts to an expanded multi-year compute deal with Meta and a new partnership with Anthropic. While the community is actively debating the stock's long-term potential in AI infrastructure, enthusiasm is tempered by concerns over the concurrent announcement of a $3.5 billion convertible note offering and its potential for shareholder dilution.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors anticipate the upcoming topline Phase 2/3 OptimUM-02 trial results for its lead asset, darovasertib, in metastatic uveal melanoma. The community is actively discussing the potential for an accelerated approval filing and a commercial-stage transition, with many traders closely monitoring for high-volume price action and potential institutional accumulation ahead of the data release.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently at the center of a high-stakes tug-of-war between institutional short-sellers like Michael Burry and bullish retail investors fueled by a public endorsement from President Trump. The community is sharply divided, debating whether the recent price volatility represents a structural AI software correction or a temporary dip driven by competing narratives, while traders closely watch for the impact of massive government contracts on the stock's long-term momentum.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. (ALOY) is experiencing significant market volatility and trending as traders react to a recent public offering and intense community debate over its long-term viability. Investors are actively discussing the company's defense-sector supply chain role, recent contract news, and the broader implications of US rare earth independence strategies, while skeptics focus on concerns surrounding dilution and the company's pre-revenue status.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant volatility and social media attention driven by speculative rumors regarding potential partnerships and high trading volume. While some community members view the token as a promising decentralized platform for the music industry, others are cautious about potential supply releases and the risks of a classic pump-and-dump scenario.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is trending due to significant institutional interest and anticipation of a major recovery, bolstered by its zero-debt position, recurring revenue model, and potential participation in high-value government defense programs like the S.H.I.E.L.D. contract. Community members are actively discussing a potential short squeeze, rotating capital from the broader space sector, and expressing frustration over management's financial reporting delays, even as they eye a major breakout toward higher price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday...

Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immuneering from a "sell" rating to a "hold" rating in a report on Saturday...

Monashee Investment Management LLC Makes New Investment in Immuneering Corporation $IMRX

Monashee Investment Management LLC acquired a new stake in Immuneering Corporation (NASDAQ:IMRX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...

Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3

Immuneering (NASDAQ:IMRX) Chief Executive Officer and co-founder Ben Zeskind told attendees at Oppenheimer's 36th Annual Healthcare Life Sciences Conference that the company is focused on improving...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat reports. One...

Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX

Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat reports...

Immuneering (NASDAQ:IMRX) Insider Purchases $24,990.00 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood purchased 5,250 shares of the business's stock in a transaction dated Friday, January 16th. The shares were...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.28	--	--	N/A
Q4 '25	-$0.31	-$0.18	42.39%	BEAT
Q3 '25	-$0.39	-$0.38	2.15%	BEAT
Q2 '25	-$0.40	-$0.40	0.07%	BEAT
Q1 '25	-$0.53	-$0.42	20.25%	BEAT

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest IMRX News

IMRXImmuneering Corp